ZE00-0388 / Mondego Bio - LARVOL DELTA

Efficacy, in vivo safety, and PK/PD studies for novel, oral, highly selective PTPN2/1 inhibitor (ZE00-0388) (AACR 2026) - "Solo treatments with ZE00-0388 demonstrated tumor growth inhibition of 81% and in combination with anti-mPD-1 complete regression of tumor in 50% of animals. ZE00-0388 has a very favorable safety profile with tolerated doses significantly above pre-clinical proof-of-concept efficacious doses, which indicates that ZE00-0388 should have a very broad therapeutic window."

PK/PD data • Preclinical • Oncology • IFNG • PTPN2

Discovery and preclinical evaluation of a potent, orally bioavailable, highly selective, small molecule PTPN2/1 inhibitor (AACR 2025) - "ZE00-0388 demonstrated complete tumor remission in combination with the anti-mPD-1 recombinant mAb therapy in the murine colon adenocarcinoma MC38 in vivo model. ZE00-0388 demonstrates good safety and tolerability; its ADME properties confirm that ZE00-0388 is suitable for further development for combination therapies."

Preclinical • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • IFNG • PTPN2